

DEPARTMENT OF HEALTH AND HUMAN SERVICES  
FOOD AND DRUG ADMINISTRATION

DISTRICT OFFICE ADDRESS AND PHONE NUMBER

4040 N. Central Expwy., Suite 300  
Dallas, TX. 75204  
(214) 253-5200

DATE(S) OF INSPECTION

2/12-15/02

FEI NUMBER

1000220451

NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT IS ISSUED

TO: Carlton F. Hazlewood, Ph.D., IRB Chairman

FIRM NAME

Burzynski Research Institute IRB

STREET ADDRESS

9432 Old Katy Rd. Suite 370

CITY, STATE AND ZIP CODE

Houston, TX. 77055

TYPE OF ESTABLISHMENT INSPECTED

Institutional Review Board

DURING AN INSPECTION OF YOUR FIRM (I) (WE) OBSERVED:

1. Protocol [REDACTED] received tentative IRB approval on 9-16-99 and then received final IRB approval on 10-28-99. The IRB has failed to keep a copy of the [REDACTED] protocol and informed consent form
2. While the [REDACTED] study received final IRB approval on 10-28-99, it has not (to date) received any progress reports from the principal investigator.
3. While the [REDACTED] study protocol was removed from the IRB's list of active studies, there is no final report from the principal investigator to show that the [REDACTED] study was terminated and to assure that all reports of injuries/SAE's were reported during the conduct of the [REDACTED] study.
4. The IRB issued a provisional approval for the special exception (compassionate exception) request of [REDACTED] however, it failed to assure that FDA approval was obtained by the principal investigator prior to commencement of treatment.
5. The IRB accepted 2 special exception requests, one that is unsigned [REDACTED] and one signed by a research associate [REDACTED] instead of being signed by the principal investigator or co-investigator.
6. There is no record that the IRB reviewed and approved the following protocols: [REDACTED] and [REDACTED]
7. Special Exceptions receive provisional approval via expedited review exercised by the chairperson or co-chair. The BRI's IRB SOP 3, (3.4 Expedited Review) does not provide a provision for such provisional approvals.
8. A letter dated 3-30-01 states that the IRB reviewed the new pump, [REDACTED] Pump Model [REDACTED] and full board approval was granted on 3-29-01. The meeting minutes dated 3-29-01 do not document full board review and final voting results of approval.
9. Expedited review approval was given to a change in protocol and informed consent form for study [REDACTED]. The revised protocol and informed consent form are not on file.

SEE  
REVERSE  
OF THIS  
PAGE

EMPLOYEE(S) SIGNATURE

*[Handwritten Signature]*

EMPLOYEE(S) NAME AND TITLE (Print or Type)

Joel Martinez, Investigator  
Patrick D. Stone, Investigator

DATE ISSUED

2-15-02